BRIDGEWATER, N.J., Feb. 20, 2019 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that Will Lewis, Chairman and Chief
Executive Officer of Insmed, will present at the Leerink
Partners 8th Annual Global Healthcare Conference in New
York on Wednesday, February 27, 2019 at 3:30
p.m. ET.
The presentation will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. The webcast will be archived for a period of 30
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is ARIKAYCE®
(amikacin liposome inhalation suspension), which is approved in
the United States for the
treatment of Mycobacterium avium complex (MAC) lung disease
as part of a combination antibacterial drug regimen for adult
patients with limited or no alternative treatment options. MAC lung
disease is a rare and often chronic infection that can cause
irreversible lung damage and can be fatal. Insmed's earlier-stage
clinical pipeline includes INS1007, a novel oral reversible
inhibitor of dipeptidyl peptidase 1 with therapeutic potential in
non-cystic fibrosis bronchiectasis and other inflammatory diseases,
and INS1009, an inhaled formulation of a treprostinil prodrug that
may offer a differentiated product profile for rare pulmonary
disorders, including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-leerink-partners-8th-annual-global-healthcare-conference-300798390.html
SOURCE Insmed Incorporated